Compare FWRD & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | STRO |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.5M | 507.6M |
| IPO Year | 2024 | N/A |
| Metric | FWRD | STRO |
|---|---|---|
| Price | $15.97 | $22.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $37.50 | $31.33 |
| AVG Volume (30 Days) | ★ 1.1M | 439.0K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.86 | $0.72 |
| 52 Week High | $32.47 | $43.85 |
| Indicator | FWRD | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 32.68 |
| Support Level | $15.28 | $19.11 |
| Resistance Level | $23.55 | $27.96 |
| Average True Range (ATR) | 1.04 | 2.29 |
| MACD | 0.16 | -0.86 |
| Stochastic Oscillator | 97.44 | 5.57 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.